-->

Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Mar 31, 2019
Dec 31, 2018
Sep 30, 2018
Jun 30, 2018
Total Revenue
400,745
353,214
391,706
372,845
Cost of Revenue
89,182
75,019
78,893
79,019
Gross Profit
311,563
278,195
312,813
293,826
Operating Expenses
Research Development
183,591
175,390
161,408
175,582
Selling General and Administrative
162,158
164,171
148,566
153,280
Non Recurring
--
--
--
--
Others
19,765
6,782
18,580
10,227
Total Operating Expenses
365,514
346,343
328,554
339,089
Operating Income or Loss
(53,951)
(68,148)
(15,741)
(45,263)
Income from Continuing Operations
Total Other Income/Expenses Net
1,423
26,893
2,121
22,742
Earnings Before Interest And Taxes
(46,230)
(36,157)
(8,290)
(17,958)
Interest Expense
6,727
7,154
11,123
11,219
Income Before Tax
(52,957)
(43,311)
(19,413)
(29,177)
Income Tax Expense
3,516
(39,661)
(6,793)
(12,385)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(56,473)
(3,650)
(12,620)
(16,792)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(56,473)
(3,650)
(12,620)
(16,792)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(56,473)
(3,650)
(12,620)
(16,792)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information